SEC Form 4 · accession 0001209191-18-009186
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hafrun Fridriksdottir
Officer — Executive VP, Global R&D
Period of report
Feb 9, 2018
Accepted (ET)
Feb 12, 2018 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1,F2 | $18.61 | Feb 9, 2018 | A | 123,288 | A | — | Feb 8, 2028 | Ordinary Shares | 123,288 | 123,288 | D |
| Restricted Share UnitsF3,F4,F2 | — | Feb 9, 2018 | A | 48,361 | A | — | — | Ordinary Shares | 48,361 | 48,361 | D |
Explanation of responses
- F1Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.
- F2The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F3Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F4Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.